scholarly journals Australian National Enterovirus Reference Laboratory annual report, 2015

2020 ◽  
Vol 44 ◽  
Author(s):  
Jason A Roberts ◽  
Linda K Hobday ◽  
Aishah Ibrahim ◽  
Thomas Aitken ◽  
Bruce R Thorley

Australia conducts surveillance for cases of acute flaccid paralysis (AFP) in children less than 15 years as recommended by the World Health Organization (WHO) as the main method to monitor its polio-free status. Cases of AFP in children are notified to the Australian Paediatric Surveillance Unit or the Paediatric Active Enhanced Disease Surveillance System and faecal specimens are referred for virological investigation to the National Enterovirus Reference Laboratory. In 2015, no cases of poliomyelitis were reported from clinical surveillance and Australia reported 1.2 non-polio AFP cases per 100,000 children, meeting the WHO performance criterion for a sensitive surveillance system. Two non-polio enteroviruses, enterovirus A71 and coxsackievirus B3, were identified from clinical specimens collected from AFP cases. Australia complements the clinical surveillance program with enterovirus and environmental surveillance for poliovirus. Two Sabin-like polioviruses were isolated from sewage collected in Melbourne in 2015, which would have been imported from a country that uses the oral polio vaccine. The global eradication of wild poliovirus type 2 was certified in 2015 and Sabin poliovirus type 2 will be withdrawn from oral polio vaccine in April 2016. Laboratory containment of all remaining wild and vaccine strains of poliovirus type 2 will occur in 2016 and the National Enterovirus Reference Laboratory was designated as a polio essential facility. Globally, in 2015, 74 cases of polio were reported, only in the two remaining countries endemic for wild poliovirus: Afghanistan and Pakistan. This is the lowest number reported since the global polio eradication program was initiated.

2020 ◽  
Vol 44 ◽  
Author(s):  
Jason A Roberts ◽  
Linda K Hobday ◽  
Aishah Ibrahim ◽  
Bruce R Thorley

Australia monitors its polio-free status by conducting surveillance for cases of acute flaccid paralysis (AFP) in children less than 15 years of age, as recommended by the World Health Organization (WHO). Cases of AFP in children are notified to the Australian Paediatric Surveillance Unit or the Paediatric Active Enhanced Disease Surveillance System and faecal specimens are referred for virological investigation to the National Enterovirus Reference Laboratory. In 2016, no cases of poliomyelitis were reported from clinical surveillance and Australia reported 1.38 non-polio AFP cases per 100,000 children, meeting the WHO performance criterion for a sensitive surveillance system. Several non-polio enteroviruses, coxsackievirus A6, enterovirus A71, enterovirus A74 and enterovirus D68, were identified from clinical specimens collected from AFP cases. The global withdrawal of Sabin poliovirus type 2 from oral polio vaccine occurred in April 2016. This event represents the start of the polio endgame with an increased focus on the laboratory containment of all remaining wild and vaccine strains of poliovirus type 2. The National Enterovirus Reference Laboratory was designated as a polio essential facility as part of this process. In 2016, 37 cases of wild polio were reported with three countries remaining endemic: Afghanistan, Nigeria and Pakistan. Nigeria was declared polio-free in 2015, after 12 months without detection of wild poliovirus, but was reinstated as an endemic country after the reporting of four cases in August 2016. This is a salient reminder of the need to maintain sensitive surveillance for poliovirus until global eradication is certified.


2017 ◽  
Vol 102 (4) ◽  
pp. 362-365 ◽  
Author(s):  
Julie Garon ◽  
Manish Patel

The decades long effort to eradicate polio is nearing the final stages and oral polio vaccine (OPV) is much to thank for this success. As cases of wild poliovirus continue to dwindle, cases of paralysis associated with OPV itself have become a concern. As type-2 poliovirus (one of three) has been certified eradicated and a large proportion of OPV-related paralysis is caused by the type-2 component of OPV, the World Health Assembly endorsed the phased withdrawal of OPV and the introduction of inactivated polio vaccine (IPV) into routine immunisation schedules as a crucial step in the polio endgame plan. The rapid pace of IPV scale-up and uptake required adequate supply, planning, advocacy, training and operational readiness. Similarly, the synchronised switch from trivalent OPV (all three types) to bivalent OPV (types 1 and 3) involved an unprecedented level of global coordination and country commitment. The important shift in vaccination policy seen through global IPV introduction and OPV withdrawal represents an historical milestone reached in the polio eradication effort.


2021 ◽  
Vol 45 ◽  
Author(s):  
Matthew B Kaye ◽  
Arnau Garcia-Clapes ◽  
Linda K Hobday ◽  
Aishah Ibrahim ◽  
Presa Chanthalavanh ◽  
...  

Australia monitors its polio-free status by conducting surveillance for cases of acute flaccid paralysis (AFP) in children less than 15 years of age, as recommended by the World Health Organization (WHO). Cases of AFP in children are notified to the Australian Paediatric Surveillance Unit or the Paediatric Active Enhanced Disease Surveillance System and faecal specimens are referred for virological investigation to the National Enterovirus Reference Laboratory. In 2020, no cases of poliomyelitis were reported from clinical surveillance; Australia reported 1.09 non-polio AFP cases per 100,000 children, thereby meeting the WHO’s performance criterion for a sensitive surveillance system. The non-polio enteroviruses coxsackievirus A10 and coxsackievirus A16 were identified from clinical specimens collected from AFP cases. Australia also performs enterovirus surveillance and environmental surveillance to complement the clinical system focussed on children. In 2020, there were 140 cases of wild poliovirus reported from the two remaining endemic countries: Afghanistan and Pakistan. Another 28 countries reported cases of circulating vaccine-derived poliovirus.


2020 ◽  
Vol 44 ◽  
Author(s):  
Jason A Roberts ◽  
Linda K Hobday ◽  
Aishah Ibrahim ◽  
Bruce R Thorley

Australia monitors its polio-free status by conducting surveillance for cases of acute flaccid paralysis (AFP) in children less than 15 years of age, as recommended by the World Health Organization (WHO). Cases of AFP in children are notified to the Australian Paediatric Surveillance Unit or the Paediatric Active Enhanced Disease Surveillance System and faecal specimens are referred for virological investigation to the National Enterovirus Reference Laboratory. In 2017, no cases of poliomyelitis were reported from clinical surveillance and Australia reported 1.33 non-polio AFP cases per 100,000 children, meeting the WHO performance criterion for a sensitive surveillance system. Three non-polio enteroviruses, coxsackievirus B1, echovirus 11 and enterovirus A71, were identified from clinical specimens collected from AFP cases. Australia established enterovirus and environmental surveillance systems to complement the clinical system focussed on children and an ambiguous vaccine-derived poliovirus type 2 was isolated from sewage in Melbourne. In 2017, 22 cases of wild polio were reported with three countries remaining endemic: Afghanistan, Nigeria and Pakistan.


2014 ◽  
Vol 2 (2) ◽  
Author(s):  
Jayakrishnan Thayyil ◽  
Thejus Jayakrishnan

In 1988, the World Health Organization (WHO) resolved to eradicate poliomyelitis globally. Since then, the initiative has reported dramatic progress in decreasing the incidence of poliomyelitis and limiting the geographical extent of transmission. 2013 is recorded as the second consecutive year not reporting wild poliovirus (WPV) from India. If the country can retain this position for one more year India will be declared as polio eradicated. What should be the future vaccination strategies? We searched and reviewed the full text of the available published literature on polio eradication via PubMed and examined Internet sources and websites of major international health agencies. The oral polio vaccine (OPV) has been the main tool in the polio eradication program. Once WPV transmission is interrupted, the poliomyelitis will be caused only by OPV. India could expect 1 vaccine-associated paralytic polio per 4.2-4.6 million doses of OPV. Considering the threat of vaccine-derived viruses to polio eradication, WHO urged to develop a strategy to safely discontinue OPV after certification. The ultimate aim is to stop OPV safely and effectively, and eventually substitute with inactivated polio vaccine (IPV). The argument against the use of IPV is its cost. From India, field based data were available on the efficacy of IPV, which was better than OPV. IPV given intradermally resulted in seroconversion rates similar to full-dose intramuscular vaccine. The incremental cost of adopting IPV to replace OPV is relatively low, about US $1 per child per year, and most countries should be able to afford this additional cost.


Viruses ◽  
2021 ◽  
Vol 13 (7) ◽  
pp. 1355
Author(s):  
Magda Rojas-Bonilla ◽  
Angela Coulliette-Salmond ◽  
Hanen Belgasmi ◽  
Kimberly Wong ◽  
Leanna Sayyad ◽  
...  

Environmental surveillance was recommended for risk mitigation in a novel oral polio vaccine-2 (nOPV2) clinical trial (M5-ABMG) to monitor excretion, potential circulation, and loss of attenuation of the two nOPV2 candidates. The nOPV2 candidates were developed to address the risk of poliovirus (PV) type 2 circulating vaccine-derived poliovirus (cVDPV) as part of the global eradication strategy. Between November 2018 and January 2020, an environmental surveillance study for the clinical trial was conducted in parallel to the M5-ABMG clinical trial at five locations in Panama. The collection sites were located upstream from local treatment plant inlets, to capture the excreta from trial participants and their community. Laboratory analyses of 49 environmental samples were conducted using the two-phase separation method. Novel OPV2 strains were not detected in sewage samples collected during the study period. However, six samples were positive for Sabin-like type 3 PV, two samples were positive for Sabin-like type 1 PV, and non-polio enteroviruses NPEVs were detected in 27 samples. One of the nOPV2 candidates has been granted Emergency Use Listing by the World Health Organization and initial use started in March 2021. This environmental surveillance study provided valuable risk mitigation information to support the Emergency Use Listing application.


2021 ◽  
Vol Special Issue (2) ◽  
pp. 102-111
Author(s):  
Marcellin Mengouo Nimpa ◽  
Noëline Ravelomanana Razafiarivao ◽  
Annick Robinson ◽  
Mamy Randriatsarafara Fidiniaina ◽  
Richter Razafindratsimandresy ◽  
...  

Background: In 1988, the World Health Assembly launched the Global Polio Eradication Initiative. WHO AFRO is close to achieve this goal with the last wild poliovirus detected in 2014 in Borno States in Nigeria. The certification of the WHO African Region requires that all the 47 member states meet the critical indicators for a polio free status. Madagascar started implementing polio eradication activities in 1996 and was declared polio free in June 2018 in Abuja. This study describes the progress achieved towards polio eradication activities in Madagascar from 1977- 2017 and highlights the remaining challenges to be addressed. Methods: Data were collected from the national routine immunization services, Country Acute Flaccid surveillance databases and national reports of SIAS and Mop Up campaign. Country complete polio and immunization related documentation provided detailed historical information’s. Results: From 1997 to 2017, Madagascar reported one wild poliovirus (WPV) outbreak and four circulating Vaccine Derived Polio Virus (cVDPV) oubreaks with a total of 21 polioviruses (1 WPV and 21 cVDPV). The last WPV and cVDPV were notified in 1997 in Antananarivo and 2015 in Sakaraha health districts respectively. Madagascar met the main polio surveillance indicators over the last ten years and made significant progress following the last cVDPV2 outbreak in 2014 -2015. In addition, the country successfully implemented the switch from trivalent Oral Polio Vaccine (tOPV) to bivalent Oral Polio vaccine (bOPV) and containment activities. Environmental Surveillance established since 2015 did not reveal any poliovirus. The administrative coverage of the 3rd dose of oral polio vaccine (OPV3) varied across the years from 55% in 1991 to a maximum of 95% in 2007 before a progressive decrease to 86% in 2017. The percentage of AFP cases with more than 3 doses of oral polio vaccines increased from 56% in 2014 to 88% in 2017. A total of 19 supplementary immunization activities (SIA) were conducted in Madagascar from 1997 to 2017, among which 3 were subnational immunization days (sNID) and 16 were national immunization days (NIDs). Poor routine coverage contributed to the occurrence of cVDPC outbreaks in the country; addressing this should remain a key priority for the country to maintain the polio free status. From 2015 to June 2017, Madagascar achieved the required criteria leading to the acceptance of the country’s polio-free documentation in June 2018 by ARCC. However, continuous efforts will be needed to maintain a highly sensitive polio surveillance system with emphasis on security compromised areas. Finally strengthening the health system and governance at all levels will be necessary if these achievements are to be sustained. Conclusions: High national political commitment and support of the Global Polio Eradication Partnership were critical for Madagascar to achieve polio free status. Socio-political instability, weakness of the health system, sub-optimal routine immunization performance, insufficient SIA quality and existing security compromised areas remain critical program challenges to address in order to maintaining the polio free status. Continuous high-level advocacy should be kept in order to ensure that new government authorities maintain polio eradication among the top priorities of the country.


2019 ◽  
Vol 11 (1) ◽  
Author(s):  
Raymond S. Dankoli

ObjectiveTo evaluate Vaccine Derived Polio Virus 2 isolation rate from Environmental Surveillance and its contribution to Polio Eradication Initiative (PEI)IntroductionNigeria is the only country in Africa yet to be certified free of Wild Polio Virus (WPV). The country consists of 36 States and a Federal Capital Territory. Gombe is one of the 19 Polio high risk States in the North-eastern geo-political zone of the country. The last case of WPV isolated in Gombe State was in 2013.One of the strategies for Polio eradication is a sensitive Acute Flaccid Paralysis (AFP) surveillance system in which any AFP is promptly detected and timely investigated. The focus of the investigation is to analyze two faecal samples of the patient, and/or sometimes those from contacts for any possible isolation of Polio Virus1 (PV). AFP surveillance is meant to be applicable to any human population at any time; however, there are situations in which there are good reasons to suspect that negative results of AFP surveillance are not reliable. Supplementary information is required in such situations and one approach for that is Environmental Surveillance (ES), in which a search for PV is made in environmental specimens contaminated by human feaces2ES in the African region started in Nigeria in July 20113,4. Since the introduction of this strategy, it has achieved its objective of complimenting the AFP surveillance system. There has been a gradual increase in the number of ES sites in Nigeria from 2011 to date4. The increase is largely due to the successes recorded in terms of the PV isolation from the sites, PV epidemiology, the large population size and mobility4,5. The last cases of WPV1 and WPV3 from environmental samples had dates of collection in May 2014 (Kaduna) and July 2012 (Kano) respectively4.ES was initiated in Gombe State in December 2016. Four ES sites were identified and sample collection began soon after training of personnel responsible for collection of the sewage sample. The four identified ES sites are Baba Roba Valley, Unguwauku Railway Bridge, Gadan Bayan Moonshine and Dan Gusau Bridge. Since inception of ES in Gombe State, 2 ambiguous Vaccine Derived Poliovirus type 2 (aVDPV2) were confirmed from sewage samples collected from Baba Roba Valley site on the 30th January 2017 and from Dan Gusau Bridge site on the 6th March 2017. In 2018, a circulating Vaccine Derived Poliovirus type 2 (cVDPV2) was also detected from sewage samples collected on the 9th April 2018 from Baba Roba Valley site. We reviewed the laboratory results from the 2 surveillance methods so as to evaluate the VDPV2 isolation rate.MethodsES involves collection of one litre of environmental sample (sewage water) via grab sampling method in accordance with World Health Organization’s (WHO) Guidelines for Environmental Surveillance for Polioviruses2. All ES sewage samples were transported in a 1 litre container appropriately packaged in a Giostyle with 8 frozen icepacks to maintain reverse cold chain to a Polio Laboratory where the samples are analyzed as per WHO ES testing standard operating procedures. Poliovirus type 2 isolates are sent to the reference laboratory at the US Centre for Disease Control for sequencing for PV isolation.We reviewed all the results of the environmental samples (ES) and stool samples from patients with Acute flaccid paralysis (AFP) from January 2017 to June 2018. The environmental samples were from five pre-selected sites that was based on the perceived risks for polio circulation that included poor sanitation, overcrowding, extend of drainage population, availability of sewage system and absence of discharge into the sites. The stool samples were from patients detected with AFP in Gombe local government area.The results from the two methods of surveillance for PV were evaluated and compared based on yields and isolates (Negative results, VDPV2, Non-polio enterovirus (NPENT).ResultsA total of 309 sewage samples from five (5) sites and 142 AFP stool samples from Gombe LGA were collected from January 2017 to June 2018. Three 3(0.97%) of the sewage samples yielded VDPV2, 102(33.01%) had Non-polio enteroviruses (NPENT) and 41 (13.27%) negative samples. On the other hand, no VDPV was isolated from the AFP stool samples, the NPENT detection rate was 13(9.16%) and 121(85.21%) samples were negative. The Non-polio AFP (NPAFP) and stool adequacy rates for Gombe LGA during the reporting period were calculated to be 17.2 and 100% respectively.ConclusionsThe polio virus (VDPV) isolation from ES in this review is higher than in AFP surveillance. This has demonstrated amongst others benefit of ES its ability to detect polio virus even in the absence of the virus among AFP cases. ES can thus detect virus that are probably missed by AFP surveillance and hence allow for early response so as to curtail further transmission. The high NPAFP and stool adequacy rates are indication of a sensitive surveillance system nonetheless, the virus isolation from the AFP surveillance was very low. It is important to mention here that other laboratory indicators were not factored into this review. We recommend therefore that both ES and AFP surveillance be done together where facility, resources and personnel are available to implement.References[1] WHO. Field guide for supplementary activities aimed at achieving polio eradication, publication no. WHO/EPI/GEN/95.1. Geneva: World Health Organization, 1995.[2] WHO. Guidelines for environmental surveillance of poliovirus circulation. World Health Organization 2003,Department of Vaccines and Biologicals, 2003. (http://www.who.int/vaccines-documents/DoxGen/H5-Surv.htm). Accessed 6 October 2010.[3] Nicksy Gumede et al. Status of environmental surveillance in the African Regional. African health monitor. March 2015 Issue 19: Pg 38-41[4] Ticha Johnson Muluh et al. Contribution of Environmental Surveillance Toward Interruption of Poliovirus Transmission in Nigeria, 2012–2015. The Journal of Infectious Diseases, Volume 213, Issue suppl_3, 1 May 2016, Pages S131–S135, https://doi.org/10.1093/infdis/jiv767[5] Humayun Ashgar et al. Environmental Surveillance for Polioviruses in the Global Polio Eradication Initiative. The Journal of Infectious Diseases, Volume 210, Issue suppl_1, 1 November 2014, Pages S294–S303, https://doi.org/10.1017/S095026881000316X 


2020 ◽  
Vol 44 ◽  
Author(s):  
Linda K Hobday ◽  
Aishah Ibrahim ◽  
Matthew E Kaye ◽  
Leesa Bruggink ◽  
Presa Chanthalavanh ◽  
...  

Australia monitors its polio-free status by conducting surveillance for cases of acute flaccid paralysis (AFP) in children less than 15 years of age, as recommended by the World Health Organization. Cases of AFP in children are notified to the Australian Paediatric Surveillance Unit or the Paediatric Active Enhanced Disease Surveillance System and faecal specimens are referred for virological investigation to the National Enterovirus Reference Laboratory. In 2019, no cases of poliomyelitis were reported from clinical surveillance and Australia reported 1.34 non-polio AFP cases per 100,000 children, meeting the World Health Organization’s performance criterion for a sensitive surveillance system. The non-polio enteroviruses coxsackievirus A2, coxsackievirus A16, echovirus 9, and enterovirus A71 were identified from clinical specimens collected from AFP cases. Australia also performs enterovirus and environmental surveillance to complement the clinical system focussed on children. In 2019, 175 cases of wild polio were reported, with three countries remaining endemic: Afghanistan, Nigeria and Pakistan.


2013 ◽  
Vol 18 (38) ◽  
Author(s):  
E Anis ◽  
E Kopel ◽  
S R Singer ◽  
E Kaliner ◽  
L Moerman ◽  
...  

Israel was certified as polio-free country in June 2002, along with the rest of the World Health Organization European Region. Some 11 years later, wild-type polio virus 1 (WPV1) was isolated initially from routine sewage samples collected between 7 and 13 April 2013 in two cities in the Southern district. WPV1-specific analysis of samples indicated WPV1 introduction into that area in early February 2013. National supplementary immunisation with oral polio vaccine has been ongoing since August 2013.


Sign in / Sign up

Export Citation Format

Share Document